Skip to content

A multicenter study for efficacy and safety of endostar combined with chemotherapy for the treatment of relapsed or metastasis breast cancer

A multicenter study for efficacy and safety of endostar combined with chemotherapy for the treatment of relapsed or metastasis breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021961
Enrollment
Unknown
Registered
2019-03-18
Start date
2019-04-12
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Test group:endostar plus chemotherapy

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Sign the informed consent; 2)Age=18 and 3 months; 11)Contraceptive measures must be taken during treatment.

Exclusion criteria

Exclusion criteria: 1) A history of allergies to biological agents; 2) did not recover from the toxic reaction of previous treatment to 0-1 degrees (CTC AE 4.0); 3) There is uncontrolled central nervous system metastasis; 4) There are important organ dysfunction and severe heart disease, including congestive heart failure, uncontrollable arrhythmia, angina requiring long-term medical treatment, heart valve disease, myocardial infarction, and patients with refractory hypertension; 5) Women during pregnancy or lactation; 6) There are uncontrolled infections, thrombosis, bleeding risks, etc.; 7) There are chronic diseases that are not well controlled, such as diabetes, high blood pressure, peptic ulcer, chronic hepatitis, mental illness, etc.; 8) The investigator believes that the study is not suitable; 9) The patient has a history of other malignant tumors, except for cured skin basal cell carcinoma and cervical cancer.

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Secondary

MeasureTime frame
objective response rate;overall survival;

Countries

China

Contacts

Public ContactWang xiaojia

Zhejiang Cancer Hospital

peteadam@yeah.net+86 0571-88122508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026